Stroke, either ischemic or hemorrhagic, accounts for significantly high morbidity and mortality rates around the globe effecting millions of lives annually. For the past few decades, ultrasound has been extensively investigated to promote clot lysis for the treatment of stroke, myocardial infarction, and acute peripheral arterial occlusions, with or without the use of tPA or contrast agents. In the age of modern minimal invasive techniques, magnetic resonance imaging-guided high-intensity focused ultrasound is a new emerging modality that seems to promise therapeutic utilities for both ischemic and hemorrhagic stroke. High-intensity focused ultrasound causes thermal heating as the tissue absorbs the mechanical energy transmitted by the ultrasonic waves leading to tissue denaturation and coagulation. Several in-vitro and in-vivo studies have demonstrated the viability of this technology for sonothrombolysis in both types of stroke and have warranted clinical trials. Apart from safety and efficacy, initiation of trials would further enable answers regarding its practical application in a clinical setup. Though this technology has been under study for treatment of various brain diseases for some decades now, relatively very few neurologists and even neurosurgeons seem to be acquainted with it. The aim of this review is to provide basic understanding of this powerful technology and discuss its clinical application and potential role as an emerging viable therapeutic option for the future management of stroke.
Introduction
Every year about 15 million people worldwide have stroke, out of which more than one third die and nearly the same number of people suffer permanent disability.
1 It is the fifth leading cause of death in United States effecting more than 795,000 people and claiming more than 140,000 (1 out of every 20) deaths annually. 2 After the recent advancement in intra-arterial therapy, mechanical thrombectomy has been established as usual care for acute ischemic stroke (AIS) patients with proximal large vessel occlusion. [3] [4] [5] [6] [7] [8] [9] The focus has now shifted toward decreasing the door to groin time which could lead to quicker thrombectomies and eventually better outcomes. [10] [11] [12] [13] In the current era of modern minimal invasive techniques, magnetic resonance imaging-guided high-intensity focused ultrasound (MRgHIFU) is a new emerging modality that promises therapeutic utilities for multiple neurological pathologies. 14, 15 Minimally invasive techniques used to destroy deep tissue for example laser photocoagulation, microwave ablation, and radio frequency ablation use a probe or an antenna for delivering electromagnetic waves. High-intensity focused ultrasound (HIFU) causes thermal heating as the tissue absorbs the mechanical energy transmitted by the ultrasonic waves. Intensity-dependent rise in temperature at the focus of the beam leads to tissue denaturation, coagulation, and hence ablation. 16 Though this technology has been under study for treatment of various brain diseases for some decades now, relatively few neuroscientists, neurologists, and neurosurgeons seem to be familiar with it. The aim of this extensive review is to provide physicians, neurologists, and clinical neuroscientists with some basic understanding of this powerful technology and discuss its role as an emerging therapeutic option for the future management of stroke.
History
The literature revels that Aristotle was the first one to hypothesize the propagation sound waves via air particles 17 and the Roman engineer Vitruvius was the one who verified this hypothesis by defining the mechanism of transmission of sound waves in the last century BC. 18 Ultrasonic waves (frequency > 20,000 Hz) are sound waves which propagate through matter. The piezoelectric (PZT) effect has been described to produce such ultrasonic waves via application of electric field to PZT crystals. The crystals expand and contract with internal dipole structure realignments, transforming electrical energy to mechanical ultrasonic waves. 19, 20 The use of ultrasound (US) imaging for therapeutic purposes in medicine began in the early last century after it was utilized by Paul Lengevin for detecting submarines during the First World War. 21, 22 Since 1938, US transducers have been used for therapeutic purposes. [23] [24] [25] Currently, HIFU technology is being used for the treatment of many disease conditions 26, 27 (Fig 1) . In the early intervention days, diagnostic US imaging was used to guide HIFU. The frequencies used for diagnostic medical US imaging are generally in the range of 1-18 MHz, while those used for HIFU therapy are in the range of 220-680 KHz. Prostate tumor's ablation was undergone assisted by rectally inserted US imaging transducer. 28 US imaging demonstrates restricted guidance accuracy and inability to determine real-time temperature 29, 30 which led to the use of magnetic resonance imaging (MRI) for guidance. 31 MRI provides the best combination of intended target or tumor margin detection, detailed interpretation of adjacent anatomy, and intraprocedural monitoring of temperature changes. In MRgHIFU, the presonication volume target is identified by MR imaging and postsonication temperature is measured by proton resonance frequency shift by means of fast gradient-echo sequences in addition to identifying the ablated volume by T2-weighted fast spin-echo pulse sequences.
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The Basic Principles and Mechanism of Action
Heating of any tissue to 57°C for 1 second (or an equivalent thermal dose) denatures protein which leads to 100% cell death. In MRgHIFU technique, a minute brain target is heated with FUS waves. This process is called sonication, in which the MRI functions as the surgeon's eyes for aiming and the FUS waves work as the surgeon's knife. The area of tissue exposed to the temperature and the length of exposure to this heat defines an By definition, sound is a form of mechanical energy that transmits across any medium in the form of waves. Therefore, like the definition suggests, provided that a medium is present sound can transfer energy from its source to another area. Sonic intensity (SI) is defined as a time-average rate of sonic energyflow through a unit area (SI unit: W/cm 2 ). High-intensity US usually used for ultrasonic surgery has intensity (I SATA ) greater than 5 W/cm 2 , which can transmit sufficient energy required to cause coagulation necrosis of the targeted tissue. 33 HIFU therapy utilizes US waves as carriers to propagate energy through tissues. HIFU used for pallidotomy (for PD), thalamotomy (ET), capsulotomy (for OCD), and tumor thermocoagulation in the body has intensity (I SATA ) 100-10,000 W/cm 2 . The main aim is to maximize accumulation of energy at the target area in order to prompt significant biological reactions without causing injury to the tissues nearby the target area.
The Transducer
A focused PZT transducer (Fig 2) outside the body is used to converge ultrasonic energy (usually 1-3 MHz for noninvasive applications) into a tissue target and produce localized tissue destruction. The hemispheric-phased array transducer has a diameter of about 31 cm and a 15.5 cm radius of curvature. The hemispheric geometry allows for US conduction through the entire skull. It is assembled with 500-1,500 single PZT tube elements which can be operated independently. Each element emits a single beam, all of which are focused at the geometric center of the transducer to create a sharp focus. This focus can be easily navigated within a radius of 3.0 cm in any direction without causing any substantial phase distortion. The "focal zone" is the only position where the US intensity (energy per unit area) is high enough to produce change in the tissue and create a lesion. A mid-frequency (650 kHz) transducer can create small lesions that are ellipsoidal in shape, are 8-15 mm long, and have typically 1-2 mm diameter. The use of diagnostic imaging modalities such as MRI allows for noninvasive identification of the target and assists in monitoring of response.
Attenuation of Energy
As the HIFU energy passes through different layers of tissues (soft tissue, bone, etc), the intensity of the beam becomes weak. This energy loss is mainly due to diminution by both absorption and scattering of energy from interfaces or inhomogeneities within the tissue layers. If the regions of bone and air can be neglected, comparatively little energy will be lost at each tissue interface before reaching the intended target.
The Thermal Mechanisms of Action
HIFU exposure can be either constant (principally used to induce heating) or pulsed, which causes acoustic cavitation. US can be transformed to thermal energy chiefly through excess of molecular relaxation processes, which occurs following US excitation. US waves cause vibration or rotation of molecules or part of macromolecules in the tissue, this produces frictional heat. Depending on the temperature and the duration of contact, when the temperatures in excess of 56°C are maintained for more than or equal to 2 seconds, this leads to coagulative necrosis due to protein denaturation, cellular destruction, and tissue stiffening. 31, 34, 35 Thermal damage causes unplanned cell death in response to cellular insult in which the architecture of the tissue is typically conserved. These targeted cells maintain their outline as coagulation of cellular proteins occurs and their metabolic activity comes to a halt. 36 When dealing with soft tissue, it has been found that HIFU lesions histologically demonstrate a necrotic center and a border of functionally impaired glycogen-poor cells which ultimately fade leaving a sharp rim between the affected and unaffected tissues 48 hours postexposure. 37 This has been described as an "island and moat" presentation in which the "island" symbolizes an area of coagulation necrosis, while the "moat" denotes to the surrounding rim-like area that is 6-10 cells thick and is made up of cells lacking glycogen stores that generally die within the next 48 hours. 37 A strong acute inflammatory reaction follows which causes the detachment of these cells from each other and their basement membrane. Chronic inflammation and remodeling occurs which involves cellular regeneration, proliferation, migration, fibroblasts infiltration, and removal of debris that persists for a few months. 38, 39 These sonicated lesions eventually scar as they get encapsulated by granulation tissue. 37 
The Mechanical Mechanisms of Action
The pulsed or nonthermal method of HIFU exposure can cause rapid changes in tissue pressure, described as the peak rarefaction pressure amplitude (PRPA). For every type of tissue, there exists a threshold PRPA at which acoustic cavitation can occur leading to the creation of gas or liquid-filled cavities along points of weaknesses. 40 An example of these "weakness points" are the interfaces between different layers of tissue or fluid-filled structures. Cavitation occurs when the negative component of the acoustic wave causes liquid components to fail under tension, resulting in the formation of gas and vapor-filled "cavities" or bubbles. These bubbles vibrate at large displacement amplitudes exerting shear stress on the adjacent tissue as a result instigating mechanical tearing. The technique by which these bubbles expand and collapse very rapidly causing disruption of the cellular membrane and destroying the surrounding tissue structure is known as histotripsy. Cavitation-damaged tissue, the tissue exposed to histotripsy, histologically shows emulsification and regions filled with acellular debris produced by mechanical fractionation of the tissue. 41 Acoustic cavitation in the tissues primarily depends on US intensity and the frequency employed by the device, the higher the frequency, the higher the intensity required to induce cavitation. In comparison to the mechanical-pulsed method, the thermal effect is more accurately predictable; therefore, it is easily controlled and allows for safe therapy.
The Apparatus and Setup
HIFU treatments for different tumors and other chronic diseases are usually carried out in a single session, often as a day case procedure. The patient is kept either fully conscious, lightly sedated, or under light general anesthesia as needed for their comfort. The treatment is carried out in the interventional radiology suite and the typical setup consists of an MRI machine with thermometry, a dosimetry workstation, a stereotactic head frame, a transducer, a positioning system, and a water cooling, circulation, and degassing system (Fig 3) . The transducer can either be moveable or fixed to the MRI table.
The patient's head is shaved to allow for an adequate acoustic window. Gel pads or a silicone diaphragm is then fixed to the scalp and the transducer is filled with degassed water (dissolved oxygen below 1.2 ppm). This provides a gas-free interface between the skin and the transducer. Circulation of cooled (15-20°C) degassed water is carried out between the sonications to avoid any unnecessary heating and to lower the temperature of skull (Fig 4) .
Sonothrombolysis in Stroke Ischemic Stroke
For the past few decades, US has been identified to promote clot breakdown for the treatment of stroke, myocardial infarction, and acute peripheral arterial occlusions, with or without the use of thrombolytic drugs or contrast agents. [42] [43] [44] [45] [46] [47] [48] Some clinical trials have also been carried out combining Doppler ultrasonography and tPA resulting in not so promising outcomes. [49] [50] [51] [52] [53] [54] The CLOTBUST trial and the TRanscranial low-frequency Ultrasound-Mediated thrombolysis in Brain Ischemia (TRUMBI) trial were the first clinical trials to use the combination therapy of unfocused US with tPA for clot-lysis. 49, 50 The CLOTBUST trial showed ineffectiveness, while the TRUMBI trial was stopped early because of high incidence of hemorrhages. Alexandrov et al, Eggers et al, and Molina et al also demonstrated mixed outcomes. [51] [52] [53] Combined lysis of thrombus with ultrasound and systemic tPA for emergent revascularization in acute ischemic stroke (CLOTBUST-ER) was a randomized controlled, double-blind phase 3 clinical trial which was terminated in 2015 after enrollment of 675 participants and the results of the trial have not been published yet. 54 However, all these trials have used unfocused Doppler or low-frequency US for sonothrombolysis. Moreover, the use of tPA led to high hemorrhage rates in these trials. The use of unfocused beams has demonstrated off target effects because of the presence of standing waves. 50, 55 Conversely, with the use of HIFU, the formation of standing waves is diminished. 56 The large area-focused arrays apply US energy at a very small, predefined target site only without affecting the majority of brain tissue. Numerous preclinical studies have demonstrated HIFU to be a favorable option for thrombolysis with or without tPA, both in-vitro and in-vivo models.
57-65
In-Vitro HIFU Studies
Westermark et al and Rosenschein et al were the first to demonstrate the in-vitro use of HIFU in a pulsed mode to cause rapid clot breakdown without using thrombolytic drugs. 57, 58 They found pulsing HIFU to be more efficient than either continuous HIFU or lithotripsy shockwaves and credited this increase in efficiency to the activity of cavitation induced by the pulsing technique. Later, in 2009, Maxwell et al investigated the use of noninvasive histotripsy for thrombolysis of in-vitro 300 mg clots formed from fresh canine blood using a 1-MHz transducer. 60 They demonstrated targeted tissue fractioning of blood clots using appropriate US pulse sequences and used US to monitor the treatment based on tissue changes and cavitation feedback. They argued that the thrombolysis rates with histotripsy were faster (1.5-5 minutes) than those for drugs and since it does not require the complex practice of inserting a catheter into the treatment site, it would also require less time and lower cost than mechanical thrombectomy.
In 2011, Hölscher et al were the first to demonstrate noninvasive transcranial clot lysis using HIFU within 30 seconds without the use of tPA. 66 The study was performed using hemispheric-phased array transducer consisting of 1,000 single piezo elements (ExAblate TM 4000 -InSightec Inc., Tirat Carmel, Israel) on different cadaveric skulls. A total of 420 clots were successfully lysed with fluctuating acoustic powers output (between 100 and 400 W) under altering flow mechanics. Further, HIFU sonothrombolysis studies carried out on larger number (total N = 2,000), all demonstrated substantial clot lysis within seconds of exposure.
Cui et al studied the viability of laser-enhanced cavitation HIFU treatment for thrombolysis of bovine blood clots without any thrombolytic agents or microbubbles. 63 They found that thrombolytic efficacy increased with laser illumination as laserenhanced cavitation significantly reduced the cavitation threshold for alone HIFU sonothrombolysis. Recently, Suo et al used multifrequency HIFU for thrombolysis and demonstrated that dual frequency was much better than single-frequency under the same acoustic power and excitation conditions. 65 It was also noted that dual-frequency US can save up to 30% sonication power in order to attain the equivalent thrombolytic efficacy.
In-Vivo HIFU Studies
After the first transcranial cadaveric study for HIFU clot lysis, Holscher et al carried out the first in-vivo study using the rabbit carotid artery model. 67 The carotid artery of a rabbit provides similar arterial dimensions as the M1/M2 segments of a human middle cerebral artery (MCA) and also mimics its bifurcation which is the most common site for embolic occlusions. Moreover, it is ideal for real-time monitoring of flow and clot mechanics using diagnostic US during the HIFU procedures. The ExAblate TM 4000 HIFU head system was used for sonothrombolysis and clot specimens were visualized with scanning electron microscopy for structural changes (Fig 5) . However, the vascular wall damage caused due to exposure to HIFU waves was not histologically assessed in this study.
Burgess et al also demonstrated the viability of technology as a standalone method for effective thrombolysis in rabbits. 62 In contrast to Holscher et al, this study was carried out under MR-guidance (MRgHIFU) and pre and postangiograms as well as histological assessment was done to evaluate reperfusion and vascular endothelial damage. Successful recanalization was achieved in 50% and 70% of the animals which were treated using 415 and 550 W of acoustic power, respectively, without damaging the targeted arteries (Fig 6) . This study confirmed that HIFU could be a safe stand-alone option for effective Thrombus specimens after HIFU exposure human (E × 10,000, G × 20,000) and rabbit (F × 10,000, H × 20,000) demonstrating disaggregation of the fibrin fiber network with single fibers covered with cellular matrix (dust). The effect was found to be more prominent in human thrombi compared to rabbit specimens. (Credit: Image published with permission from Springer Nature-Transl Stroke Res, Holscher et al 67 ) thrombolysis. In 2014, Pajek and colleagues investigated the use of intravascular perfluorocarbon (PFC) droplets to reduce the sonication powers required for HIFU thrombolysis. 64 It was observed that there was a reduction in inertial cavitation threshold and successful recanalization was accomplished in rabbit models of embolic stroke at 24 ± 5% of the power without PFC droplets. They also suggested that with the reduction in acoustic power and the use of transducers with precision focus, HIFU thrombolysis can be achieved successfully within the main arteries of human brain without causing any vascular damage and bleeding of the sonicated vessels. A recent preclinical study examined combination therapy of HIFU and a neuroprotective agent BNG-1 in an acute carotid thrombotic occlusion model using light-emitting diode (LED) irradiation in rat to improve the thrombolytic effect of rt-PA. 68 As apparent from numerous preclinical studies, HIFU sonothrombolysis has lately emerged as a favorable tPA-free option for the treatment of AIS. [60] [61] [62] [63] [64] [65] HIFU causes microbubble oscillation which causes mechanical disruption of the blood clot improving flow restoration. 69 It reduces the quantity of tPA required for effective treatment. Previously, it has been demonstrated that combination of low-intensity US and microbubble contrast agents improves thrombolysis both with or without tPA. [69] [70] [71] [72] However, HIFU of 1 MHz is linked with enhanced thrombolysis as compared to lower frequencies. 73 The following table highlights progression timeline in the development of HIFU technology for the thrombolysis in AIS (Table 1) .
Hemorrhagic Stroke
Intracerebral hemorrhage (ICH) accounts for 10-15% of the worldwide strokes annually leading to significant morbidity and mortality. 78, 79 It is most commonly caused by hypertension, arteriovenous malformations, cerebral aneurysms, amyloid angiopathy, head traumas, or blood thinner therapy and has the highest mortality rate of all stroke subtypes. 80, 81 Current management varies from managing hypertension, coagulopathy, or draining hydrocephalus to sometimes more aggressive surgical intervention. Spontaneous ICH or aneurysmal subarachnoid hemorrhage can lead to intraventricular hemorrhage (IVH) with an expected mortality of 50-80%. Several attempts have been made to device a treatment plan for ICH and IVH given their associated morbidity and mortality. The STICH (International Surgical Trial in Intracerebral Haemorrhage) and STICH II trials did not establish any substantial advantage of surgical removal over conservative management for ICH. 82, 83 The results of CLEAR III trial for thrombolytic removal of IVH also did not show any promising results either. 84 The results of MISTIE II (Minimally Invasive Surgery and rt-PA in ICH Evacuation) trial have been encouraging and the results from the ongoing phase III trial (MISTIE III) are highly anticipated. 85, 86 MRgHIFU seems to provide another promising platform for minimally invasive treatment of ICH and IVH. Numerous in-vitro and in-vivo studies have validated the feasibility of MRgHIFU for clot lysis of ICH without the use of tPA. [74] [75] [76] [77] Monteith et al in in-vitro and cadaveric models of ICH demonstrated fast, effective, and accurate thrombolysis using MRgHIFU. 75 Harnof et al also proved the technique to be safe and efficient for sonothrombolysis in in-vivo swine model of ICH and ex-vivo models using a human calvaria. 77 It can facilitate a highly controlled sonothrombolysis to remove ICH and IVH clots with extreme precision under realtime MRI observation followed by clot removal using twist-drill craniostomy and aspiration tube. 87 Clot lysis is confirmed by increased T2-weighted signal changes on intraoperative MRI providing the ability to decide when to stop and carry out aspiration of the lysate. 88 Contrary to the present catheter-based approaches in which the catheter needs to be placed along the long axis of the clot for maximal dissolution, the shape of clot does not cause any concern with MRgHIFU and the procedure can be easily repeated if required due to its minimalinvasiveness. With the just simple adjustment of parameters on the computer software, an HIFU lesion can be made in the septum pellucidum of casted ventricle to augment CSF circulation between the lateral ventricles, boost dissolution of blood clot, and improve hydrocephalus thereby allowing for a multimodal treatment of ICH and IVH without even moving the patient or the transducer. Furthermore, cadaveric studies by Monteith et al have also demonstrated the possibility of treating hydrocephalus from an IVH via an incisionless third ventriculostomy or fenestration of the lamina terminalis. 74 Although the current shape of the transducer dose limits beam steering such that the clots within 2 cm to the skull surface are unable to be targeted, however, this issue may eventually be resolved as the technology advances further. For now, it seems that the technology is ideal for efficient lysis of deep, central hemorrhages or IVH as these lesions are in the perfectly accurate spot for the transducers and require less navigation of the HIFU waves. After the initial promise shown by preclinical studies, clinical trials incorporating this technology to treat ICH and IVH are expected to begin soon.
Future Application and Potential in a Clinical Setup
In the acute management of stroke, the importance of time is undeniable. As stroke remains one of the leading causes of death globally, treatment options that promote faster clot lysis and decrease the incidence of intracerebral bleeding thereby improving patient outcomes are of immense value and worth every effort. HIFU is an emerging innovative technology with the potential to achieve clot lysis within few seconds, faster than unfocused sonothrombolyisis. When combined with imaging modalities as MRI, used to evaluate stroke patients, MRgHIFU could affectedly decrease the time to accomplish flow restoration in stroke from hours to just few minutes, resulting in significant reductions in infarct size and better clinical outcomes. Moreover, it seems to be more advantageous as a potentially standalone method for thrombolysis as it minimizes the possibility of hemorrhaging transformation by eliminating the side effects of thrombolytic agents. When compared with mechanical thrombectomy, HIFU does not require insertion of catheter into the treatment site and the complications associated with it could potentially cause effective thrombolysis without damaging the target vessel at a lower cost. In the emergent setting, MRgHIFU can be an alternative therapeutic tool for physicians treating patients with clots also located other than in proximal vessels. Other intracranial vessel locations such as anterior cerebral arteries, posterior cerebral arteries, and distal MCA branches (called M3, M4 branches) are hard to reach endovascular and carry a high risk for perforation related to mechanical manipulation. Therefore, MRgHIFU may provide the ability to offer clot-lysis in both small and large vessel occlusion catering to a larger acute stroke patient population. When dealing with ICH and IVH, MRgHIFU seems to offer the capability to lyse an intracerebral thrombus with precision followed by minimally invasive aspiration. More importantly, MRI immediate information demonstrates the degree of clot lysis and removal along with any evidence of potential complications during the procedure. The technology eliminates the use of indwelling catheters or tubes in the brain that may lead to various complications such as infection, malfunction, or breakage. There is also no necessity for tPA, which might worsen edema. Furthermore, the procedure becomes safer without tPA as the chances of worsening of edema and risk of hemorrhage at the ICH site or down the catheter tract are diminished.
In a world with limited resources, healthcare economics plays an important role. As with any new technology, the direct and indirect cost associated with it determines its acceptance into healthcare system across the globe. Therefore, it is imperative that present day emerging modalities not only be cost-effective but have the potential to further expand their therapeutic applications across a broad range of diseases. The cost of the system (Transducer) is about USD 2 million. The one time high initial setup cost upfront for the MRgHIFU system along with the associated 3-T MRI scanner might seem prohibitive. However, the 3-T MRI scanner is a widely used regular diagnostic device in hospitals all around the world where neurosurgical procedures are performed. The technology clearly has a wide range of application as it has been approved for the treatment of multiple neurological conditions. It also exhibits immense expansive potential as preclinical studies for several other conditions, including stroke, have demonstrated favorable results warranting clinical trials. It appears to provide noninvasive treatment option for a number of drug refractory neurological diseases as well as central nervous system (CNS) pathologies that require surgical intervention. Moreover, the decrease in indirect expenses associated with craniotomies, thrombectomies, postoperative length of stay, and medications seems to strengthen the case in its favor. When acquired by a hospital, most of the treatments would be planned day procedures except in the case of stroke. In such emergent conditions, ideally a patient with ischemic or hemorrhagic stroke will be diagnosed in the emergency department after routine CT imaging. The patient will then be transferred to the MRsuite for immediate noninvasive sonothrombolysis which can be followed by minimally MR-guided aspiration in case of ICH. When not in use, the MRI scanner can be used for regular diagnostic purpose. Other than the MRI technician, additional staff as an US engineer is required to support treatments with the MRgHIFU system. However, a pilot clinical trial will help us better understand the glitches in its practical application and how to overcome these initial short comings as well as other unidentified technicalities in a clinical setting. One known adverse effect of the technology can be the bone lesions that occur in regions of low skull density ratio. 89 Therefore, in future studies, the correlation between location of the clot and local skull properties should be considered.
Conclusion
This emerging therapeutic modality seems to have great potential to revolutionize the existing treatment paradigms of ischemic and hemorrhagic stroke and warrants further investigations and well-designed clinical trials.
